patients who received intramuscular vector injection. This study was completed with preclinical mouse muscle and liver IS analyses derived from wild-type mice injected intramuscularly or intravenously with AAV1-LPL S447X , respectively. 1969 exact mappable AAV IS were detected in patient muscle, 1735 in mouse muscle and 892 in mouse liver, respectively, while the AAV vector integrated with a frequency of 10 -4 to 10 -5 into humans. Most AAV-derived LAM-PCR amplicons represented concatemeric rearrangements with large inverted terminal repeat deletions. In respect to gene coding regions, CpG-islands and palindromic regions the integration pattern was largely random. In the analyzed patient muscle, two AAV IS-hotspots were identifi ed showing homology to the mitochondrial (mt) genome. In mouse muscle, three hotspots were observed, one homolog to the mtDNA genome and two in the muscle specifi c nuclear genes Myh and Ttn. Interestingly, no prominent hotspot was detected after intravenous AAV1-LPL S447X injection into mice. Similar sequences present in both the nuclear and the mt genome have been previously described, termed nuclear mitochondrial DNA (NUMT). Therefore, we made use of direct sequencing of enriched murine mtDNA by the MiSeq technology to prove the occurrence of AAV IS in the mt genome. These data confi rmed the previously obtained data by LAM-PCR and showed further that AAV breakage might occur at each vector nucleotide position indicating that the integration frequency is underestimated by 1log. In total, these data are unique in their context and promising for the fi eld of clinical AAV gene therapy. Furthermore, AAV preference for the mtDNA differs from the elucidated AAV traffi cking route from the endosome to the nucleus and may broaden AAV vector application.
Ex Vivo Lentiviral Gene Therapy as a Cure for Murine Pompe Disease
Merel Stok, 1 Helen de Boer, 1 Marshall W. Huston, 1 Edwin H. Jacobs, 2 Onno Roovers, 1 Holger Jahr, 3 Dirk J. Duncker, 4 Trudi P. Visser, 1 Ans T. van der Ploeg, 5 Arnold J. J. Reuser, 5 Nico P. van Til, 1 Gerard Wagemaker. 1 1 Hematology, Erasmus Medical Center, Rotterdam, Netherlands; 2 Genetics, Erasmus Medical Center, Rotterdam, Netherlands; 3 Orthopedics, Erasmus Medical Center, Rotterdam, Netherlands; 4 Experimental Cardiology, Erasmus Medical Center, Rotterdam, Netherlands; 5 Pediatrics, Center for Lysosomal and Metabolic Diseases, Erasmus Medical Center, Rotterdam, Netherlands. Pompe disease is a lysosomal storage disease caused by mutations in the gene encoding for acid alpha-glucosidase (GAA) and is characterized by systemic storage of glycogen, leading to progressive muscle weakness and, in its most severe form, to death from cardiac and respiratory failure within the fi rst year of life. Enzyme replacement therapy (ERT) is the current standard of treatment, but is not curative, not benefi cial to all patients, frequently results in antibodies against the recombinant enzyme, while costs are high. We developed in a Gaa-/-mouse model an ex vivo lentiviral vector mediated hematopoietic stem cell (HSC) gene therapy strategy, using a vector containing an expression improved GAA sequence. Transplantation after mild conditioning resulted in approximately 30 % transduced stem cells with the majority of the blood cell system untouched and in life-long high levels of (human) alpha-glucosidase in leukocytes and all affected tissues. Supranormal levels of GAA activity resulted in normal levels of glycogen and full functional restoration of heart and skeletal muscle. Contrary to ERT, the strategy normalized glycogen levels in brain tissue, likely attributable to microglia descending from transduced HSCs, with GAA demonstrated in astrocytes, recently shown to play an essential physiologic role in glycogen storage and neuronal glucose and lactate metabolism. Furthermore, glycogen levels were highly reduced in cartilage. In line with the intrinsic tolerogenic nature of HSC transplantation, immune reactions proved to be absent after highly immunogenic challenging with human GAA. Thus, ex vivo lentiviral vector mediated HSC gene therapy corrects the Pompe phenotype in the Gaa-/-mouse model, warranting further development toward clinical implementation in the most severely affected infantile form of Pompe disease.
Pathogenesis of Growth Failure in Murine and Canine Glycogen Storage Disease-Ia and Partial Reversal of Growth Failure Using Adeno-Associated Viral Vector Therapy
Elizabeth J. Brooks, 1 Dianne Little, 2 Ramamani Arumugam, 1 Baodong Sun, 1 Sarah Curtis, 1,3 Amanda DeMaster, 1,4 Michael Maranzano, 1 Mark W. Jackson, 5 Priya Kishnani, 1 Michael S. Freemark, 1 Dwight D. Koeberl. 1 1 Pediatrics, Duke University Medical Center, Durham, NC; 2 Orthopaedic Surgery, Duke University Medical Center, Durham, NC; 3 Rehoboth Beach Animal Hospital, Rehoboth Beach, DE; 4 East Lincoln Animal Hospital, Denver, NC; 5 Animal Health and Comparative Medicine, University of Glasgow, Glasgow, United Kingdom. Glycogen Storage Disease type Ia (GSD-Ia) is an autosomal recessive disorder that causes glucose-6-phosphatase (G6Pase) defi ciency. In humans, GSD-Ia frequently causes incongruent bone age, decrease in fi nal adult height, and decreased growth velocity. This study evaluates growth failure and the effect of gene therapy in GSD-Ia affected dogs and mice. Here we show that gene therapy with an adeno-associated virus 9 pseudotyped vector expressing G6Pase (AAV2/9-G6Pase; 1E+13 vector particles/kg at 2 days of age) partially corrected growth in GSD-Ia affected dogs as detected by weight and bone measurements. At 7 weeks of age, AAV2/9-G6Pase treated GSD-Ia dogs weighed 1038±226 g, (n=7) while unaffected littermates weighed 2153±472 g, (n=22); however, affected dogs that received dietary therapy alone only achieved 565±15 g, (n=2) at the same age.
Low serum insulin-like growth factor I (IGF-I) persisted despite gene therapy in affected dogs. Moreover, homozygous G6Pase (-/-) mice with GSD-Ia have normal growth hormone (GH) levels in response to hypoglycemia, decreased IGF-I levels, and attenuated weight gain following administration of GH. Expression of hepatic GH receptor and IGF-I mRNAs and hepatic STAT5 (phospho Y694) protein levels are reduced prior to and after GH administration, indicating GH resistance. However, restoration of G6Pase expression in the liver by treatment with AAV2/8-G6Pase (1E+13 vector particles/kg at 14 days of age) corrected IGF-I in plasma and body weight in comparison with age-matched wild type mice. Untreated G6Pase (-/-) mice also demonstrated severe delay of secondary ossifi cation at their growth plates at 12 days of age and those treated with AAV2/8-G6Pase at
